REHOVOT, Israel, April 13, 2022 /PRNewswire/ — CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medication firm growing modern applied sciences and merchandise for tissue regeneration and organ manufacturing, at present introduced that Dr. Jasmine Seror, CollPlant’s Head of Aesthetic Medication and Exploratory Merchandise, will ship a presentation on the Aesthetics Innovation Summit 2022, to be held in San Diego, California, on Wednesday, April 20, 2022.
The presentation, entitled “Novel photocurable rhCollagen implants for regenerative aesthetics functions,” might be delivered nearly on the highlight session on regenerative medication & cell remedy at 11:20 AM EST.
Presentation title: “Novel photocurable rhCollagen implants for regenerative aesthetics functions”
Date: Wednesday, April 20, 2022
Time: 11:20 AM EST
Registration Hyperlink: click here
CollPlant is a regenerative and aesthetic medication firm targeted on 3D bioprinting of tissues and organs, and medical aesthetics. The Firm’s merchandise are based mostly on its rhCollagen (recombinant human collagen) produced with CollPlant’s proprietary plant based mostly genetic engineering expertise. These merchandise handle indications for the various fields of tissue restore, aesthetics, and organ manufacturing, and are ushering in a brand new period in regenerative and aesthetic medication.
Initially of 2021, CollPlant entered right into a growth and international commercialization settlement for dermal and smooth tissue fillers with Allergan, an AbbVie firm, the worldwide chief within the dermal filler market. Later in 2021, CollPlant entered a strategic co-development settlement with 3D Programs for a 3D bioprinted regenerative smooth tissue matrix to be used in breast reconstruction procedures together with an implant.
For extra details about CollPlant, go to http://www.collplant.com
Secure Harbor Statements
This press launch could embody forward-looking statements. Ahead-looking statements could embody, however will not be restricted to, statements regarding CollPlant’s targets plans and techniques, in addition to statements, aside from historic information, that handle actions, occasions or developments that CollPlant intends, expects, tasks, believes or anticipates will or could happen sooner or later. These statements are sometimes characterised by terminology equivalent to “believes,” “hopes,” “could,” “anticipates,” “ought to,” “intends,” “plans,” “will,” “expects,” “estimates,” “tasks,” “positioned,” “technique” and related expressions and are based mostly on assumptions and assessments made in gentle of administration’s expertise and notion of historic traits, present circumstances, anticipated future developments and different elements believed to be acceptable. Ahead-looking statements will not be ensures of future efficiency and are topic to dangers and uncertainties that would trigger precise outcomes to vary materially from these expressed or implied in such statements. Many elements may trigger CollPlant’s precise actions or outcomes to vary materially from the actions and outcomes anticipated in forward-looking statements, together with, however not restricted to, the next: the Firm’s historical past of serious losses, its means to proceed as a going concern, and its want to boost extra capital and its incapacity to acquire extra capital on acceptable phrases, or in any respect; the affect of the COVID-19 pandemic; the Firm’s expectations relating to the timing and price of commencing medical trials with respect to tissues and organs that are based mostly on its rhCollagen based mostly BioInk and merchandise for medical aesthetics; the Firm’s means to acquire favorable pre-clinical and medical trial outcomes; regulatory motion with respect to rhCollagen based mostly BioInk and medical aesthetics merchandise together with however not restricted to acceptance of an software for advertising and marketing authorization assessment and approval of such software, and, if authorized, the scope of the authorized indication and labeling; industrial success and market acceptance of the Firm’s rhCollagen based mostly merchandise in 3D Bioprinting and medical aesthetics; the Firm’s means to ascertain gross sales and advertising and marketing capabilities or enter into agreements with third events and its reliance on third celebration distributors and resellers; the Firm’s means to ascertain and preserve strategic partnerships and different company collaborations; the Firm’s reliance on third events to conduct some or all elements of its product manufacturing; the scope of safety the Firm is ready to set up and preserve for mental property rights and the Firm’s means to function its enterprise with out infringing the mental property rights of others; the general international financial atmosphere; the affect of competitors and new applied sciences; basic market, political, and financial circumstances within the international locations wherein the Firm operates; projected capital expenditures and liquidity; adjustments within the Firm’s technique; and litigation and regulatory proceedings. Extra detailed details about the dangers and uncertainties affecting CollPlant is contained below the heading “Threat Elements” included in CollPlant’s most up-to-date annual report on Type 20-F filed with the SEC, and in different filings that CollPlant has made and should make with the SEC sooner or later. The forward-looking statements contained on this press launch are made as of the date of this press launch and mirror CollPlant’s present views with respect to future occasions, and CollPlant doesn’t undertake and particularly disclaims any obligation to replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case.
Contact at CollPlant:
Deputy CEO & CFO
Tel: + 972-73-2325600
Electronic mail: Eran@CollPlant.com
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/collplant-to-present-at-the-aesthetics-innovation-summit-2022-301524691.html